Skip to main content
SpringerLink
Log in

Specific Bradycardic Agents

  • Chapter
Antiarrhythmic Drugs

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 89))

Abstract

Alinidine (St 567, N-allyl-clonidine), the prototype of the novel class of drugs discussed in this section, has been classified as an antiarrhythmic agent by Millar and Vaughan Williams (1981a) on the basis of its selective electrophysiological effects upon certain myocardial cells. Unlike other agents discussed in this volume, the therapeutic goal searched for was not primarily to interfere with abnormal heart beats, but simply to reduce the sinus node controlled heart rate. In patients where a decrease in myocardial oxygen consumption is a desired therapeutic measure, this might be achieved by a decrease in heart rate (Sonnenblick and Skelton 1971). The expected benefit of a retardation in heart rate for a patient with rigid narrowing of coronary arteries is even more obvious, if the bradycardia is mainly due to a prolongation of the diastolic period, the time span which allows perfusion of the myocardium.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Amsterdam EA, Hughes JL, de Maria AN, Zelis R, Mason DT (1974) Indirect assessment of myocardial oxygen consumption in the evaluation of mechanisms and therapy of angina pectoris. Am J Cardiol 33: 737–743

    CAS  Google Scholar 

  • Arndts D, Forster HJ (1981) New aspects in the metabolism of alinidine in man. Eur J Metab Pharmacokinet 6: 313–315

    Article  CAS  Google Scholar 

  • Arndts D, Leb G, Förster HJ (1981) Pharmacokinetics and metabolism of C-labelled alinidine in man and dog. Eur J Drug Metabol Pharmacol 6: 225–236

    Article  CAS  Google Scholar 

  • Auböck, J, Konzett H, Olbrich E (1982) The effect of alinidine (St 567) on emotionally induced tachycardia in man. Eur J Clin Pharmacol 21: 467–471

    Article  PubMed  Google Scholar 

  • Balakumaran K, Lubsen J, Simoons ML, Jovanovic A, ten Cate FJ, van Es GA, Pie- terse H (1984) Anti-anginal effect of the Clonidine derivative alinidine: a comparison with metoprolol. Eur Heart J 5 [Suppl 1]: 271

    Google Scholar 

  • Bender F, Gülker H (1982) Ein neues Antiarrhythmicum (AQ-A 39) zur Behandlung von Sinustachykardien. Muench Med Wochenschr 124: 97–98

    Google Scholar 

  • Benedikter L, Trouvain H, Zimmer A (1980) Pharmacodynamics and pharmacokinetics of a new aryl-alkylamine with negative chronotropic effects in man. In: Riet- brock N, Woodcock BG, Neuhaus G (eds) Methods in clinical Pharmacol, the proceedings of an international symposium held in Frankfurt/M. 6-8 May 1979, Vieweg, Braunschweig, pp 44–45

    Google Scholar 

  • Bouman LN, Duivenvoorden JJ, Opthof T, Treytel BW (1984) Electrophysiological effects of alinidine on nodal and atrial fibres in the guinea-pig heart. J Pharmacol Exp Ther 229: 551–556

    PubMed  CAS  Google Scholar 

  • Bouman LN, Jongsma HJ, Opthof T, van Ginneken ACG (1985) Does 4 contribute to pace-making in the rabbit sinoatrial node? J Physiol 358: 51 P

    Google Scholar 

  • Clementy J, Hilaire A (1984) Electrophysiological effects of the bradycardic agent falipamil (AQ-A 39) Eur Heart J 5 [Suppl 1]:287 (abstr)

    Google Scholar 

  • Dämmgen JW, Gross GJ (1985) AQ-AH 208, a new bradycardic agent, increases coronary collateral blood flow to ischemic myocardium. J Cardiovasc Pharmacol 7: 1048–1054

    Article  Google Scholar 

  • Dämmgen J, Kadatz R, Diederen W (1981) Cardiovascular actions of 5,6-dimethoxy- 2– [3[[(a(3,4-dimethoxy)-phenylethyl]methylamino]propyl]phthalimidine (AQ- A 39), a specific bradycardic agent. Arzneim Forsch Drug Res 31: 666–670

    Google Scholar 

  • Dämmgen JW, Lamping KA, Gross G (1985) Actions of two new bradycardic agents, AQ-AH 208 and UL-FS 49, on ischemic myocardial perfusion and function. J Cardiovasc Pharmacol 7: 71–79

    Article  PubMed  Google Scholar 

  • Dennis PD, Vaughan Williams EM (1986) Further studies of alinidine induced bradycardia in the presence of caesium. Cardiovasc Res 20: 375–378

    Article  PubMed  CAS  Google Scholar 

  • Di Francesco D (1985) The cardiac hyperpolarizing-activated current, /f, origins and developments. Prog Biophys Mol Biol 46: 163–183

    Article  Google Scholar 

  • Fitzal S, Zimpfer M (1982) Cardiovascular effects of iV-allyl-clonidine (St 567, alinidine): a substance with specific bradycardic action during neuroleptanesthesia in humans. Int J Clin Pharmacol Ther Toxicol 20: 404–407

    PubMed  CAS  Google Scholar 

  • Gross GJ, Dämmgen JW (1986) Beneficial effects of two specific bradycardic agents AQ-A 39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs. J Pharmacol Exp Ther 238: 422–428

    PubMed  CAS  Google Scholar 

  • Gross GJ, Warltier DC, Dämmgen JW (1985) Effects of AQ-AH 208, a new specific bradycardic agent on myocardial ischemia-reperfusion injury in anesthetized dogs. J Cardiovasc Pharmacol 7: 929–936

    Article  PubMed  CAS  Google Scholar 

  • Gruber R, Lumper G, Zilberszac A, Heistracher P (1983) Effects of 1,3,4,5-tetrahydro- 7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]methylimino]propyl]-2H-3- benzazepin-2-on-hydrochloride (UL-FS 49 CI) on the action potential of the guinea-pig heart. Naunyn Schmiedebergs Arch Pharmacol 324:R 32

    Google Scholar 

  • Gülker H, Holtvogt J, Specker E, Thale J, Heuer H, Bender F (1986) Elektrophysiolo- gische und haemodynamische Wirkungen der neuen bradykardisierenden Substanz AQ-A 39. Z Kardiol 75: 47–51

    PubMed  Google Scholar 

  • Guth BD, Heusch G, Ross J (1987) Elimination of exercise-induced regional myocardial dysfunction by a bradycardic agent in dogs with chronic coronary stenosis. Circulation 75: 661–669

    Article  PubMed  CAS  Google Scholar 

  • Haberl R, Steinbeck G (1985) Chronotropic action of alinidine on the isolated sinus node of the rabbit heart. Eur Heart J 6: 730–736

    PubMed  CAS  Google Scholar 

  • Hageman GR, Neely BH, Urthaler F, James TH (1985) Negative chronotropic and parasympatholytic effects of alinidine on canine sinus node and AV junction. Am J Physiol 248: H324 - H330

    PubMed  CAS  Google Scholar 

  • Harron DWG, Ridell JG, Shanks RG (1981) Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet i: 351–353

    Google Scholar 

  • Harron DWG, Shanks RG (1985) Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardic agent alinidine. Eur Heart J 6: 722–729

    PubMed  CAS  Google Scholar 

  • Harron DWG Allen J, Wilson R, Shanks RG (1982 a) Effect of alinidine on experimental cardial arrhythmias. J Cardiovasc Pharmacol 4: 221–225

    Google Scholar 

  • Harron DWG, Arndts D, Shanks RG (1982 b) Alinidine pharmacokinetics following acute and chronic dosing. Br J Clin Pharmacol 13: 821–827

    Google Scholar 

  • Harron DWG, Jady K, Riddell JG, Shanks RG (1982 c) Effects of alinidine, a novel bradycardic agents, on heart rate and blood pressure in man. J Cardiovasc Pharmacol 4: 213–220

    Google Scholar 

  • Harron DWG, Arndts D, Finch M, Shanks RG (1983) An assessment of the contribution of Clonidine metabolised from alinidine to the cardiovasular effects of alinidine. Br J Clin Pharmacol 16: 451–455

    PubMed  CAS  Google Scholar 

  • Harron DWG, Brezina, M, Lillie C, Kobinger W (1985) Antifibrillatory properties of alinidine after coronary artery occlusion in rats. Eur J Pharmacol 110: 301–308

    Article  PubMed  CAS  Google Scholar 

  • Hellner KA, Gauri KK (1982) Über Akkomodationsphosphene. Fortschr Ophthalmol 79: 169–170

    PubMed  CAS  Google Scholar 

  • Herzog H, Simon H (1983) Untersuchungen zur Frequenzsenkung bei Sinustachykar- die und tachykardem Vorhofflimmern unterschiedlicher Ätiologie mit einer neuen bradykardisierenden Substanz (AQ-A 39). Herz/Kreislauf 7: 354–357

    Google Scholar 

  • Hilaire J, Broustet JP, Colle JP, Theron M (1983) Cardiovascular effects of AQ-A 39 in healthy volunteers. Br J Clin Pharmacol 16: 627–631

    PubMed  CAS  Google Scholar 

  • Hohnloser SJ, Weirich J, Homburger H, Antoni H (1982) Electrophysiological studies on effects of AQ-A 39 in the isolated guinea-pig heart and myocardial preparations. Arzneim Forsch/Drug Res 32: 730–734

    CAS  Google Scholar 

  • Jähnel C, Nawrath M (1985) Interactions of alinidine and acetylcholine in guinea pig atria. Naunyn Schmiedebergs Arch Pharmacol 329: R54

    Google Scholar 

  • Jaski BE, Serruys PW (1985) Anion-channel blockade with alinidine: a specific bradycardic drug for coronary heart disease without negative inotropic activity? Am J Cardiol 56: 270–275

    Article  PubMed  CAS  Google Scholar 

  • Jost S, Schulz W, Kober G (1985) Wirkung des neuen Kalziumantagonisten 5,6-Dime- thoxy-2-[3[[of-(3,4-dimethoxy)-phenylethyl]methylamino]propyl]-phthalimidin-hy- drochlorid (AQ-A 39 Cl) auf Hämodynamik und Ischämieparameter in Belastungs-EKG von Patienten mit koronarer Herzkrankheit. Arzneim Forsch/Drug Res 35: 1279–1282

    CAS  Google Scholar 

  • Kasper W, Meinertz T, Treese N, Kersting F, Pop T, Jähnchen E (1981) Clinical electrophysiological properties of N-allyl-clonidine (St 567) in man. J Cardiovasc Pharmacol 3: 39 - 47

    Article  PubMed  CAS  Google Scholar 

  • Kawada M, Satoh K, Taira N (1984 a) Selectivity of alinidine, a bradycardic agent, for SA nodal automaticity versus other cardiac activities in isolated, blood-perfused dog-heart preparations. Arch Int Pharmacodyn Ther 272: 88–102

    Google Scholar 

  • Kawada M, Satoh K, Taira N (1984 b) Analyses of the cardiac action of the bradycardic agent, AQ-A 39, by use of isolated, blood perfused dog-heart preparations. J Pharmacol Exp Ther 228: 484–490

    Google Scholar 

  • Khosropour R, Zimpfer M, Lackner F (1983) Slow channel calcium blockade to antagonize the chronotropic effects of isoproterenol. Anesthesiology 59: A43

    Google Scholar 

  • Kobinger W (1978) Central a-adrenergic systems as targets for hypotensive drugs. Rev. Physiol Biochem Pharmacol 81: 39–100

    Article  PubMed  CAS  Google Scholar 

  • Kobinger W (1985) Specific bradycardic agents, a new approach to therapy in angina pectoris? Prog Pharmacol 5 /4: 89–100

    CAS  Google Scholar 

  • Kobinger W (1986) Drugs as tools in research on adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 332: 113–123

    Article  PubMed  CAS  Google Scholar 

  • Kobinger W, Lillie C (1987) Specific bradycardic agents - a novel pharmacological class? Eur Heart J 8 (Suppl L): 7–15

    Google Scholar 

  • Kobinger W, Lillie C (1984 a) Alinidine. In: Scriabine A (ed) Cardiovascular drugs. Raven, New York, pp 193–210 (New drugs annual, vol 2)

    Google Scholar 

  • Kobinger W, Lillie C (1984b) Cardiovascular characterization of UL-FS 49, 1,3,4,5- tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]methylimino]- propyl]-2H-3-benzazepin-2-on-hydrochloride, a new “specific bradycardic agent”. Eur J Pharmacol 104: 9–18

    Article  PubMed  CAS  Google Scholar 

  • Kobinger W, Lillie C (1987) Specific bradycardic agents - a novel pharmacological class? Eur Heart J 8 (Suppl L): 7–15

    PubMed  CAS  Google Scholar 

  • Kobinger W, Lillie C, Pichler L (1979 a) N-Allyl-derivative of Clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn Schmiedebergs Arch Pharmacol 306: 255–262

    Google Scholar 

  • Kobinger W, Lillie C, Pichler L (1979b) Cardiovascular actions of iV-allyl-clonidine (St 567), a substance with specific bradycardic action. Eur J Pharmacol 58: 141–150

    Article  PubMed  CAS  Google Scholar 

  • Krähenmann R, Heistracher P (1980) Electrophysiological studies of the effects of 5,6-dimethoxy-2-[3-[[a-(3,4-dimethoxy)phenylethyl]methylamino]propyl]phthali- midine (AQ-A 39) in isolated cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 311: R36

    Google Scholar 

  • Kray er O (1949) Studies on veratrum alkaloids. VIII. Veratramine, an antagonist to the cardioaccelerator action of epinephrine. J Pharmacol Exp Ther 96: 422–437

    PubMed  CAS  Google Scholar 

  • Krumpl G, Mayer N, Schneider W, Raberger G (1986 a) Effects of alinidine on exercise-induced regional contractile dysfunction in dogs. Eur J Pharmacol 130: 37–46

    Google Scholar 

  • Krumpl G, Schneider W, Raberger G (1986b) Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents? Naunyn Schmiedebergs Arch Pharmacol 334: 540–543

    Article  PubMed  CAS  Google Scholar 

  • Lillie C, Kobinger W (1983 a) Comparison of the bradycardic effects of alinidine (St 567), AQ-A 39 and verapamil on guinea-pig sinoatrial node superfused with different Ca2+ and NaCl solutions. Eur J Pharmacol 87: 25–33

    Google Scholar 

  • Lillie C, Kobinger W (1983 b) Actions of alinidine and AQ-A 39 on rate and contractility of guinea pig atria during /?-adrenocoptor stimulation. J Cardiovasc Pharmacol 5: 1048–1051

    Google Scholar 

  • Lillie C, Kobinger W (1984) Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol 328: 210–213

    Article  PubMed  CAS  Google Scholar 

  • Lillie C, Kobinger W (1986) Investigations into the bradycardic effects of UL-FS 49 (l,3,4,5-tetrathydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]methyli- mino]propyl]-2-3-benzazepin-2-on hydrochloride) in isolated guinea pig atria. J Cardiovasc Pharmacol 8: 791–797

    PubMed  CAS  Google Scholar 

  • Lillie C, Kobinger W (1987) Investigations differentiating the mechanism of specific bradycardic agents from that of calcium channel blockers. Naunyn Schmiedebergs Arch Pharmacol 335: 331–333

    Article  PubMed  CAS  Google Scholar 

  • Löllgen H, Just H, Wollschläger H, Kersting F (1981) Hemodynamic actions of alini- dine during exercise in patients with coronary artery disease. Z Kardiol 70: 425–428

    PubMed  Google Scholar 

  • Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, Braunwald E (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43: 67–82

    PubMed  CAS  Google Scholar 

  • Meinertz T, Kasper W, Kersting F, Wiegand U, Jähnchen E, Pop T (1980) Wirkung von Alinidine bei koronarer Herzkrankheit. Z Kardiol 69: 720

    Google Scholar 

  • Meinertz T, Kasper W, Meier R, Wiegand V, Jähnchen E (1981) Beneficial effects of alinidine in patients with angina. Circulation [Suppl IV] 64: 294

    Google Scholar 

  • Millar JS, Vaughan Williams EM (1981a) Anion antagonism—a fifth class of antiarrhythmic action? Lancet i: 1291–1293

    Google Scholar 

  • Millar JS, Vaughan Williams EM (1981b) Pacemaker selectivity: influence on rabbit atria of ionic environment and of alinidine, a possible anion antagonist. Cardio- vasc Res 15: 335–350

    Article  CAS  Google Scholar 

  • Millar JS, Vaughan Williams EM (1983) Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs. Br J Pharmacol 79: 701–709

    PubMed  CAS  Google Scholar 

  • Miyamoto J, Kotake H, Mashiba H (1986) Study on bradycardia induced by diltiazem in the rabbit sinoatrial node. Arzneim Forsch/Drug Res 36: 808–810

    CAS  Google Scholar 

  • Neill Wa, Levine HJ, Wagman RJ, Gorlin R (1963) Left ventricular oxygen utilization in intact dogs: effect of systemic hemodynamic factors. Circ Res 12: 163–169

    Google Scholar 

  • Opthof T, Duivenvoorden JJ, van Ginneken ACG, Jongsma HJ, Bouman L (1986) Electrophysiological effects of alinidine (St 567) on sinoatrial node fibres in the rabbit heart. Cardiovasc Res 20: 727–739

    Article  PubMed  CAS  Google Scholar 

  • Osterrieder W, Pelzer D, Yang Q-F, Trautwein W (1981) The electrophysiological basis of the bradycardic action of AQ-A 39 on the sinoatrial node. Naunyn Schmiedebergs Arch Pharmacol 317: 233–237

    Article  PubMed  CAS  Google Scholar 

  • Pelzer D, Trautwein W, McDonald TF (1982) Calcium channel block and recovery from block in mammalian ventricular muscle treated with organic channel inhibitors. Pflügers Arch 394: 97–105

    Article  PubMed  CAS  Google Scholar 

  • Pichler L (1982) Effect of alinidine (St 567) on sympathetic and vagal activities. Arch Int Pharmacodyn 255: 162–167

    PubMed  CAS  Google Scholar 

  • Reiterer W (1981) Belastungshämodynamik Koronarkranker nach selektiver Frequenzsenkung (Alinidine). Acta Med Austriaca 8: 182–183

    Google Scholar 

  • Reiterer W, Stanek B (1980) Einfluß von Alinidine auf die Herzfrequenz unter Ergometerarbeit. Z Kardiol 69: 707

    Google Scholar 

  • Satoh H, Hashimoto K (1986) Electrophysiological study of alinidine in voltage clamped rabbit sino-atrial node cells. Eur J Pharmacol 121: 211–219

    Article  PubMed  CAS  Google Scholar 

  • Sayen JJ, Sheldon WF, Peirce G, Kuo PT (1958) Polarographic oxygen, the epicardial electrocardiogram and muscle contraction in experimental acute regional ischemia of the left ventricle. Circ Res 6: 779–798

    PubMed  CAS  Google Scholar 

  • Schamhardt HC, Verdouw PD, Saxena PR (1981) Improvement of perfusion and function of ischemic porcine myocardium after reduction of heart rate by alinidine. J Cardiovasc Pharmacol 3: 728–738

    Article  PubMed  CAS  Google Scholar 

  • Schurmans J, Piessens J, Kesteloot H, de Geest H (1982) Comparative effect of alinidine and propranolol in ischemic heart disease. Eur J Clin Pharmacol 23: 389–396

    CAS  Google Scholar 

  • Shanks RG (1987) The clinical pharmacology of alinidine and its side effects. Eur Heart J 8 (Suppl L): 83–90

    PubMed  Google Scholar 

  • Siegl PKS, Wenger HC, Sweet CS (1984) Comparison of cardiovascular responses to the bradycardic drugs, alinidine, AQ-A 39, and mixidine, in the anesthetized dog. J Cardiovasc Pharmacol 6: 565–574

    Article  PubMed  CAS  Google Scholar 

  • Simoons ML (1985) Clinical evaluation of alinidine, a specific sinus node inhibitor. Prog Pharmacol 5[4]101–108

    Google Scholar 

  • Simoons ML, Balakumaran K (1981) The effects of drugs on the exercise electrocardiogram. Cardiology [Suppl 2] 63: 124–132

    Article  Google Scholar 

  • Simoons ML, Hugenholtz PG (1982) Alinidine, a new drug for treatment of sinus tachycardia in myocardial infarction of cardiogenic shock. Am J Cardiol 49: 980

    Article  Google Scholar 

  • Simoons ML, Hugenholtz PG (1984) Haemodynamic effects of alinidine, a specific sinus node inhibitor, in patients with unstable angina or myocardial infarction. Eur Heart J 5: 227–232

    PubMed  CAS  Google Scholar 

  • Simoons ML, Hugenholtz PG (eds) (1987) Heart rate reduction. A reinvented approach to cardiac physiology and therapy. Eur Heart J 8 (Suppl L)

    Google Scholar 

  • Simoons ML, Tummers J, van Meurs-van Woezik H, van Domburg R (1982) Alinidine, a new agent which lowers heart rate in patients with angina pectoris. Eur Heart J 3: 542–545

    CAS  Google Scholar 

  • Snyders DJ, van Bogaert PP (1985) Mode of action of alinidine, a new bradycardic agent: a voltage-clamp study. J Am Coll Cardiol 5: 494

    Google Scholar 

  • Snyders DJ, van Bogaert PP (1987) Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflügers Arch 410: 83–91

    Article  PubMed  CAS  Google Scholar 

  • Sonnenblick EH, Skelton CL (1971) Oxygen consumption of the heart: physiological principles and clinical implications. Mod Concepts Cardiovasc Dis 40: 9–16

    Google Scholar 

  • Stähle H, Daniel H, Kobinger W, Lillie C, Pichler L (1980) Chemistry, pharmacology and structure-activity relationship with a new type of imidazolines exerting a specific bradycardic action at a cardiac site. J Med Chem 23: 1217–1222

    Article  PubMed  Google Scholar 

  • Stanek B, Reiterer W, Placheta P, Raberger G (1983) Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome. Eur J Clin Pharmacol 24: 31–34

    Article  PubMed  CAS  Google Scholar 

  • Struyker-Boudier H, Smits J, van Essen H (1981) Haemodynamic effects of alinidine (St 567), a specific bradycardic agent, in the conscious spontaneously hypertensive rat. Naunyn Schmiedebergs Arch Pharmacol 316 [Suppl]: R42

    Article  Google Scholar 

  • Takeda K, Akera T, Brody TM (1980) Cardiovascular actions of mixidine fumarate. Eur J Pharmacol 68: 129–137

    Article  PubMed  CAS  Google Scholar 

  • Traunecker W, Walland A (1980) Haemodynamic and electrophysiologic actions of alinidine in the dog. Arch Int Pharmacodyn 244: 58–72

    PubMed  CAS  Google Scholar 

  • Trautwein W, Pelzer D, McDonald TF, Osterrieder W (1981) AQA 39, a new bradycardic agent which blocks myocardial calcium ( Ca) channels in a frequency and voltage-dependent manner. Naunyn Schmiedebergs Arch Pharmacol 317: 228–232

    Google Scholar 

  • Trautwein W, Pelzer D, McDonald TF (1983) Interval- and voltage-dependent effects of the calcium channel-blocking agents D 600 and AQA 39 on mammalian ventricular muscle. Circ Res 52 [Suppl I]: 60–68

    CAS  Google Scholar 

  • Tritthart HA, Windisch H, Heuberger S (1981) The effects of the bradycardia-produ- cing compound alinidine on action potentials and tension development in cardiac fibres. Naunyn Schmiedebergs Arch Pharmacol 316: 172–177

    Article  PubMed  CAS  Google Scholar 

  • Urthaler F, Walker AA (1984) Indirect stimulatory action of the calcium channel blocker AQ-A 39. J Pharmacol Exp Ther 230: 336–340

    PubMed  CAS  Google Scholar 

  • Van Bogaert P-P, Gothals M (1987) Pharmacological influence on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules. Eur Heart J 8 (Suppl L): 35–42

    PubMed  Google Scholar 

  • Vaughan Williams EM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24: 129–147

    PubMed  CAS  Google Scholar 

  • Vaughan Williams EM, Dennis PD, Garnham C (1986) Circadian rhythm of heart rate in the rabbit: prolongation of action potential duration by sustained beta adrenoceptor blockade is not due to associated bradycardia. Cardiovasc Res 20: 528–535

    Article  PubMed  CAS  Google Scholar 

  • Verdouw PD, Saxena PR, Schamhardt HC, van der Hoek TM, Rutterman AM (1980) The effects of alinidine, an 7V-allyl-derivative of Clonidine, on regional myocardial perfusion and performance in the pig with or without artrial pacing. Eur J Pharmacol 64: 209–220

    Article  PubMed  CAS  Google Scholar 

  • Verdouw PD, Gom HPA, Bijleveld RE (1983) Cardiovascular responses to increasing plasma concentrations of AQ-A 39 CI, a new compound with negative chronotropic effects. Arzneim Forsch/Drug Res 33 [l]: 702–706

    CAS  Google Scholar 

  • Warbanow W, Wallukat G, Will-Shahab L (1984) Effects of the bradycardic substance alinidine: (St 567) on cultivated heart myocytes. In: Proc 12 congress of the Ges für Kardiol und Angiol der DDR, Rostock 6-10 November 1984, p 143

    Google Scholar 

  • Wiegand UW, Kasper W, Meinertz T, Stützle U, Jähnchen E (1982) Pharmacokinetic and pharmacodynamic properties of alinidine in man. J Cardiovasc Pharmacol 4: 59–62

    Article  PubMed  CAS  Google Scholar 

  • Zetler G, Lenschow E, Prenger-Berninghoff W (1968) Die Wirkung von 11 Indol-Alkaloiden auf das Meerschweinchenherz in vivo und in vitro, verglichen mit 2 synthetischen Azepinoindolen, Chinidin und Quindonium. Naunyn Schmiedebergs Arch Pharmakol Exp Pathol 260: 26–49

    Google Scholar 

Download references

Authors
  1. W. Kobinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hertford College, Oxford University, 153 Woodstock Road, Oxford, OX2 7NA, Great Britain

    E. M. Vaughan Williams Professor Dr.

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kobinger, W. (1989). Specific Bradycardic Agents. In: Vaughan Williams, E.M. (eds) Antiarrhythmic Drugs. Handbook of Experimental Pharmacology, vol 89. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73666-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73666-7_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73668-1

  • Online ISBN: 978-3-642-73666-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation